Scientists test common Drug's impact on experimental cancer therapy
NCT ID NCT07402915
Summary
This early-phase study aims to understand how a common antifungal medication (itraconazole) affects the levels of a new, experimental cancer drug (AZD5335) in the body. It involves about 24 participants with recurrent ovarian, fallopian tube, or primary peritoneal cancer. The main goal is to measure drug interactions and safety, not to test how well the new drug fights cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
NOT_YET_RECRUITINGBatumi, 6010, Georgia
-
Research Site
NOT_YET_RECRUITINGTbilisi, 0114, Georgia
-
Research Site
NOT_YET_RECRUITINGTbilisi, 112, Georgia
-
Research Site
NOT_YET_RECRUITINGDublin, D07 R2WY, Ireland
-
Research Site
NOT_YET_RECRUITINGLisbon, 1250-068, Portugal
-
Research Site
NOT_YET_RECRUITINGBarcelona, 08023, Spain
-
Research Site
RECRUITINGLogroño, 26006, Spain
-
Research Site
RECRUITINGMadrid, 28040, Spain
-
Research Site
RECRUITINGMadrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.